Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 1
1(33.3%)
3Total
N/A(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07186088Not ApplicableNot Yet Recruiting

Therapeutic Efficacy of Different Repeated Low-Intensity Red Light Devices and Different Usage Frequencies

Role: lead

NCT07160036Not ApplicableRecruiting

Repeatability of AO-SLO (Mona IIa) Technology and Cone Cell Density of Individuals Use Repeated Low-level Red-light Therapy

Role: lead

NCT07104513Active Not Recruiting

Efficacy and Influencing Factors of Repeated Low-level Red-light in Myopia

Role: lead

NCT06523504Phase 1Recruiting

Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control

Role: lead

All 4 trials loaded